One-year mortality is higher for hemodialysis patients starting carvedilol compared to those starting metoprolol, suggests a study in the American Journal of Kidney Diseases.
The retrospective analysis included 27,064 Medicare patients starting hemodialysis in a large US dialysis organization from 2007 through 2012. All included patients who initiated beta-blocker therapy with metoprolol (64.7% of patients) or carvedilol (35.3%). These two groups were compared for the 1-year outcomes of all-cause mortality, cardiovascular mortality, and intradialytic hypotension, with adjustment for demographic, clinical, laboratory, and dialysis treatment covariates.
Propensity score analysis suggested that the two groups were highly comparable. All-cause mortality